Biosignal (ASX:BOS) listed today on the Australian Stock Exchange, with shares leaping to AUD$0.38, a premium of almost 100 per cent on its $0.20 issue price. [ + ]

A state-of-the-art cellular neurophysiology laboratory was opened today at the University of Melbourne for the National Neuroscience Facility (NNF). [ + ]

Brisbane-based GeneTraks has received a $1 million R&D Start grant from the Commonwealth government for its AUD$2.6 million equine diagnostics development project. [ + ]

Phosphagenics (ASX:POH) -– formerly Vital Capital -– has announced the successful completion of animal studies for its transdermal delivery system for morphine. [ + ]

A company formed as part of the Victorian Biotechnology Entrepreneur Program, a pilot program of Young Achievers Australia and the Victorian State Government, has returned a whopping 900 per cent to its shareholders, through the sale of its products to a scientific supplies company. [ + ]

The wallaby genome project is poised to go ahead thanks to a last minute injection of $3 million into the project by the Victorian State Government. [ + ]

Norwood Abbey's UK subsidiary Norwood Immunology has revealed its plans to float on the London Stock Exchange's Alternative Investment Market (AIM) in May. [ + ]

Technology developed by CSIRO Livestock Industries (CLI) will lead to the development of strategies designed to substantially reduce the $140 million lost each year due to Australian dairy cows contracting udder infections.

Melbourne's St Vincent's Institute of Medical Research has opened its new AUD$10.5 million medical research building on the St Vincent's Hospital campus. [ + ]

The first NSW biotechnology listing of 2004 is on the launch pad. Rather than listing in an IPO, Sydney-based BioSignal has chosen to make its debut via the back door, using as its vehicle Perth-based CTI Communications, which yesterday raised $4 million in an oversubscribed share issue and will acquire 100 percent of BioSignal’s shares. [ + ]

Bresagen's administrators have reached an in-principle agreement with Queensland-based public unlisted biotech company CBio for the restructure and relisting of the company. [ + ]

If Queensland Premier Peter Beattie fulfils his ambition of appropriating Victoria’s mantle as the Biotech State, he will be indebted to itinerant Brisbane resident Chuck Feeney. [ + ]

Having secured patent coverage for its vaccine technology, London-based Onyvax will extend its collaboration with researchers from the Queensland University of Technology and the Princess Alexandra Hospital. [ + ]

Novogen (ASX: NRT) has announced updated results from two clinical trials of its anti-cancer drug phenoxodiol, which is being developed by the company's US-based subsidiary Marshall Edwards (LSE AIM: MSH; Nasdaq: MSHL). [ + ]

Adelaide biotech Bionomics’ (ASX:BNO, OTC:BMICY) successful share placement last month has raised nearly $4 million of the $6 million needed to fast-track its epilepsy and anxiety-drug discovery program, while causing minimal angst among shareholders. [ + ]